Epigenetic Aberrations and Targets in Peripheral T-Cell Lymphoma

Area of Science:

• Oncology
• Hematology
• Molecular Biology

Background:

• Peripheral T cell lymphomas (PTCL) are aggressive hematologic malignancies with diverse subtypes.
• Current treatments, like CHOP therapy, show unsatisfactory outcomes for many PTCL patients.
• Genetic mutations affecting epigenetic modulation are increasingly recognized in PTCL subtypes.

Purpose of the Study:

• To review key genetic mutations (IDH2, TET2, DNMT3A) disrupting epigenetic pathways in PTCL.
• To discuss therapeutic agents targeting epigenetic modulation in PTCL.
• To highlight approved and investigational treatments for PTCL, focusing on refractory/relapsed disease.

Main Methods:

• Literature review of genetic mutations in PTCL.
• Analysis of epigenetic pathways (acetylation, deacetylation, methylation).
• Survey of approved and clinical trial therapies for PTCL.

Main Results:

• Specific mutations (IDH2, TET2, DNMT3A) are implicated in PTCL pathogenesis.
• Epigenetic modifying agents show promise in PTCL treatment.
• Several targeted therapies are approved or in clinical trials for refractory/relapsed PTCL.

Conclusions:

• Understanding genetic mutations and epigenetic dysregulation is crucial for PTCL treatment.
• Epigenetic therapies represent a promising avenue for improving PTCL patient outcomes.
• Personalizing treatment based on genetic profiles may address unmet needs in PTCL.